Segnalazione PI3K/Akt/mTOR
Gli inibitori della segnalazione PI3K/Akt/mTOR sono composti che bersagliano le vie della fosfoinositide 3-chinasi (PI3K), della chinasi Akt e del bersaglio della rapamicina nei mammiferi (mTOR). Queste vie sono regolatori critici della crescita cellulare, della sopravvivenza, del metabolismo e dell'autofagia, rendendole bersagli chiave nella ricerca sul cancro e nei disturbi metabolici. Inibendo queste vie è possibile aiutare a controllare la crescita e la proliferazione tumorale, offrendo potenziali strategie terapeutiche per vari tipi di cancro e altre malattie caratterizzate da una segnalazione cellulare disfunzionale. Presso CymitQuimica, offriamo una vasta selezione di inibitori PI3K/Akt/mTOR di alta qualità per supportare la tua ricerca in oncologia, segnalazione cellulare e malattie metaboliche.
Sottocategorie di "Segnalazione PI3K/Akt/mTOR"
- AMPK(159 prodotti)
- ATM/ATR(71 prodotti)
- DNA-PK(50 prodotti)
- EGFR(572 prodotti)
- MELK(7 prodotti)
- PDK(9 prodotti)
- PI3K(241 prodotti)
- Chinasi S6(9 prodotti)
- gsk-3(111 prodotti)
- mTOR(145 prodotti)
Mostrare 2 più sottocategorie
Trovati 1025 prodotti di "Segnalazione PI3K/Akt/mTOR"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Alpelisib hydrochloride
CAS:<p>Alpelisib hydrochloride (BYL-719) is an oral, selective PI3Kα inhibitor with anticancer properties.</p>Formula:C19H23ClF3N5O2SPurezza:98%Colore e forma:SolidPeso molecolare:477.93Zandelisib
CAS:<p>Zandelisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K)(p110δ, IC50 of 3.5 nM), and with antineoplastic activity.</p>Formula:C31H38F2N8OPurezza:99.88%Colore e forma:SolidPeso molecolare:576.68DNA-PK-IN-10
CAS:<p>DNA-PK-IN-10 is a DNA-PK inhibitor utilized in the research of breast cancer and non-small cell lung cancer [1].</p>Formula:C25H28N6O2Purezza:98%Colore e forma:SolidPeso molecolare:444.53PI3K/mTOR Inhibitor-1
CAS:PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual inhibitor of PI3K/mTOR (PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ/mTOR with IC50s of 20/376/204/46/186 nM)Formula:C18H22FN5O3SPurezza:98%Colore e forma:SolidPeso molecolare:407.46Sevabertinib
CAS:<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Formula:C24H25ClN4O5Purezza:99.81%Colore e forma:SolidPeso molecolare:484.93Rheb inhibitor NR1
CAS:<p>Rheb inhibitor NR1 is a Rheb inhibitor and selective mTORC1 inhibitor that promotes phosphorylation of S473pAKT.</p>Formula:C25H19BrCl2N2O3SPurezza:99.72%Colore e forma:SolidPeso molecolare:578.3EGFR/ErbB-2 inhibitor-1
CAS:<p>EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.</p>Formula:C23H15ClFN3OS2Purezza:98.93%Colore e forma:SolidPeso molecolare:467.97EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formula:C28H33N7O2Purezza:98.64%Colore e forma:SolidPeso molecolare:499.61PI3K-IN-54
CAS:<p>Compound 10w, a substituted pyrazolo[1,5-a]pyrimidinamide compound, is a ZSTK474 analog that shows anticancer activity against HeLa cells.</p>Formula:C20H24F2N8O3Purezza:98.15%Colore e forma:SolidPeso molecolare:462.45BGB-8035
CAS:<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Formula:C24H31N5O4Purezza:96.74%Colore e forma:SolidPeso molecolare:453.53EGFR-IN-1 hydrochloride
CAS:<p>EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.</p>Formula:C28H31ClN6O4Purezza:99.16%Colore e forma:SolidPeso molecolare:551.04EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Formula:C32H23ClF3N7O4Purezza:99.51%Colore e forma:SolidPeso molecolare:662.02PF-04979064
CAS:<p>PF-04979064 is a potent and selective PI3K and mTOR dual kinase inhibitor(Ki of 0.13 nM and 1.42 nM,respectively).</p>Formula:C24H26N6O3Purezza:98.20% - ≥98%Colore e forma:SolidPeso molecolare:446.5PKI-402
CAS:<p>PKI-402 is a potent PI3K and mTOR inhibitor. PKI-402 inhibits PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ with IC50s of 2, 3, 7, 14 and 16 nM, respectively.</p>Formula:C29H34N10O3Purezza:99.94%Colore e forma:SolidPeso molecolare:570.65GSK-F1
CAS:<p>GSK-F1 (PI4KA inhibitor-F1) is a novel potent PI4KA inhibitor.</p>Formula:C27H18F5N5O4SPurezza:97.03%Colore e forma:SolidPeso molecolare:603.52GSK-3 inhibitor 1
CAS:<p>GSK-3 inhibitor 1 is a GSK-3 inhibitor.</p>Formula:C22H17ClFN5O2Purezza:98.42%Colore e forma:SolidPeso molecolare:437.85GDC-0349
CAS:<p>GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.</p>Formula:C24H32N6O3Purezza:96.00% - 98.17%Colore e forma:SolidPeso molecolare:452.55EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Colore e forma:SolidGLPG3312
CAS:<p>GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .</p>Formula:C23H21F2N5O3Purezza:98.53%Colore e forma:SolidPeso molecolare:453.44EGFR-IN-132
CAS:<p>EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.</p>Formula:C27H31N7O3Colore e forma:SolidPeso molecolare:501.58GSK-3β inhibitor 7
<p>GSK-3β inhibitor 7 is a GSK-3β inhibitor (IC50: 5.25 μM).</p>Formula:C27H23BrN4O2SColore e forma:SolidPeso molecolare:547.47EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Formula:C30H35FN6O3Colore e forma:SolidPeso molecolare:546.64EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Formula:C14H11BrN4O2SColore e forma:SolidPeso molecolare:379.23DNA-PK-IN-6
CAS:<p>DNA-PK-IN-6 inhibits DNA-PKcs, disrupting tumor DNA repair and triggering apoptosis; enhances radiotherapy and targets various tumors (WO2021197159A1).</p>Formula:C19H21N7OColore e forma:SolidPeso molecolare:363.42EGFR-IN-133
CAS:<p>EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.</p>Formula:C27H29F2N7O3Colore e forma:SolidPeso molecolare:537.564-FPBUA
CAS:<p>4-FPBUA, a semi-synthetic analog of lichen acid, enhances the functionality of cell-based blood-brain barriers (BBB) and increases the transport of β-amyloid (Aβ) in monolayer cells. Additionally, it acts as an inhibitor of mTOR, enhancing cellular autophagy (Autophagy) which can reverse BBB disruption in vivo, making it relevant for research in Alzheimer's disease.</p>Formula:C31H23FO7Colore e forma:SolidPeso molecolare:526.51ES-072
CAS:<p>ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.</p>Formula:C25H27F3N8O2Colore e forma:SolidPeso molecolare:528.53EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Formula:C26H28ClN3O4Colore e forma:SolidPeso molecolare:481.97EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Formula:C27H31ClN7O3PColore e forma:SolidPeso molecolare:568.01BPI-15086
CAS:<p>BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.</p>Formula:C29H33ClN8O4Colore e forma:SolidPeso molecolare:593.08PI4KIIIbeta-IN-11
CAS:<p>PI4KIIIbeta-IN-11 is a PI4KIIIβ inhibitor (mean pIC50=9.1) that can be used to study diseases caused by RNA viruses and Plasmodium falciparum.</p>Formula:C33H39N7O3Colore e forma:SolidPeso molecolare:581.71EGFR-IN-149
CAS:<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Formula:C16H15N3OSColore e forma:SolidPeso molecolare:297.375PI3Kδ-IN-23
CAS:<p>PI3Kδ-IN-23 (compound A11) is a potent inhibitor of PI3Kδ, with an IC50 of 0.27 nM. It binds to PI3Kδ through covalent interaction with Lys779 and plays a significant role in cancer research.</p>Formula:C30H30N6O5Colore e forma:SolidPeso molecolare:554.596PI3K-IN-23
<p>PI3K-IN-23 is a (E)-9-oxooctadec-10-en-12-ynoic acid analogue that promotes glucose uptake (EC50: 7.00 μM).</p>Formula:C24H33NO4SColore e forma:SolidPeso molecolare:431.59GSK3-IN-9
CAS:GSK3-IN-9 (0713) is a selective inhibitor of glycogen synthase kinase 3 (GSK3). It holds potential for research into fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood epilepsy, intellectual disabilities, diabetes, acute myeloid leukemia (AML), autism, and mental disorders.Formula:C18H20N4OColore e forma:SolidPeso molecolare:308.378Andamertinib
CAS:<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Formula:C31H36N8O3Colore e forma:SolidPeso molecolare:568.669EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Formula:C31H30FN7OColore e forma:SolidPeso molecolare:535.61PIKfyve-IN-1
<p>PIKfyve-IN-1: potent, cell-active inhibitor for PIKfyve research, IC50=6.9 nM.</p>Formula:C20H21N5Colore e forma:SolidPeso molecolare:331.41GSK-3β inhibitor 25
CAS:<p>GSK-3β inhibitor25 (Compound 6h) exhibits weak inhibitory activity against GSK-3β with an IC50 greater than 100 μM.</p>Formula:C16H15NOSColore e forma:SolidPeso molecolare:269.361EGFR-IN-135
<p>EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.</p>Formula:C12H14N4OS2Colore e forma:SolidPeso molecolare:294.4GSK3β-IN-2
CAS:GSK3β-IN-2 (Compound S01) is an inhibitor of GSK3β with an IC50 of 0.35 nM. It activates the Wnt/β-catenin signaling pathway, promoting neurogenesis and neurite outgrowth. GSK3β-IN-2 reduces tau protein phosphorylation induced by Aβ at the Ser396 site, thereby decreasing neurofibrillary tangles. Furthermore, GSK3β-IN-2 improves Alzheimer's disease symptoms in a zebrafish model.Formula:C25H18N4OColore e forma:SolidPeso molecolare:390.437LSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Formula:C21H20ClN3O4Colore e forma:SolidPeso molecolare:413.854Sacibertinib
CAS:<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Formula:C32H31ClN6O4Colore e forma:SolidPeso molecolare:599.085-Bromo-3-indoxylacetate
CAS:<p>5-Bromo-3-indoxylacetate acts as an inhibitor of GSK-3, with a pIC50 value of 3.39.</p>Formula:C10H8BrNO2Colore e forma:SolidPeso molecolare:254.08SST0116CL1
CAS:<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Formula:C22H31ClN4O6Colore e forma:SolidPeso molecolare:482.96EGFR-IN-126
CAS:<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Formula:C28H28BrFN4O3Colore e forma:SolidPeso molecolare:567.45ETP-47037
CAS:<p>ETP-47037: strong PI3Kα inhibitor (IC50: 0.99 nM), also targets PI3Kβ, δ, γ; may protect telomeres.</p>Formula:C20H27N9O3SColore e forma:SolidPeso molecolare:473.55Tesevatinib tosylate
CAS:<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Formula:C31H33Cl2FN4O5SColore e forma:SolidPeso molecolare:663.59EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formula:C26H27ClN6O2Colore e forma:SolidPeso molecolare:490.98PI3K-IN-26
CAS:<p>PI3K-IN-26 is an effective PI3K inhibitor. PI3K-IN-26 inhibits the proliferation of SU-DHL-6 cells, IC50= 36 nM.</p>Formula:C21H18N6OSColore e forma:SolidPeso molecolare:402.47
